Enanta Pharmaceuticals financials
$12.64+0.20%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 30 | FY24 Sep 30 | FY23 Sep 30 | FY22 Sep 30 | FY21 Sep 30 | FY20 Sep 30 | FY19 Sep 30 | FY18 Sep 30 | FY17 Sep 30 | FY16 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M |
| Gross profit | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M | $122.5M | $205.2M | $206.6M | $102.8M | $88.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$85.3M | -$121.7M | -$137.2M | -$123.8M | -$109.6M | -$41.6M | $36.7M | $88.3M | $24.6M | $30.8M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M | -$79.0M | -$36.2M | $46.4M | $72.0M | $17.7M | $21.7M |
| Net margin | −125.4% | −171.6% | −169.0% | −141.3% | −81.4% | −29.5% | 22.6% | 34.8% | 17.2% | 24.5% |
| Diluted EPS | $-3.84 | $-5.48 | $-6.38 | $-5.91 | $-3.92 | $-1.81 | $2.21 | $3.48 | $0.91 | $1.13 |
| EBITDA | -$80.8M | -$119.4M | -$134.8M | -$120.9M | -$106.2M | -$38.0M | $40.0M | $90.8M | $26.8M | $32.5M |
| Operating cash flow | -$19.3M | -$78.8M | -$103.2M | -$84.8M | -$70.0M | $7.1M | $71.4M | $29.2M | $52.7M | $35.8M |
| Free cash flow | -$32.2M | -$96.7M | -$112.2M | -$86.9M | -$70.7M | $5.6M | $66.0M | $26.2M | $50.1M | $31.1M |
| Diluted shares | 21.3M | 21.2M | 21.0M | 20.6M | 20.2M | 19.9M | 21.0M | 20.7M | 19.4M | 19.2M |
Balance sheet
| Period end | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 | Sep 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $32.3M | $37.2M | $85.4M | $44.0M | $57.2M | $87.1M |
| Short-term investments | $156.6M | $211.0M | $284.5M | $205.2M | $186.8M | $299.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $280.7M | $376.7M | $462.3M | $375.4M | $438.8M | $486.1M |
| Total liabilities | $216.0M | $247.8M | $245.5M | $54.1M | $37.9M | $29.1M |
| Shareholders' equity | $64.7M | $128.8M | $216.7M | $321.3M | $400.9M | $457.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology